Skip to main content

Advertisement

SpringerLink
Log in

Incidence and pre/post-treatment risk factors of glaucoma in Vogt-Koyanagi-Harada disease

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the incidence and pre/post-treatment risk factors of glaucoma in patients with Vogt-Koyanagi-Harada (VKH) disease.

Methods

Data regarding secondary glaucoma were collected from the medical records of patients with VKH disease who were followed up at the uveitis service at Hiroshima University for more than 6 months. We examined the incidence of glaucoma and pre/post-treatment risk factors for glaucoma in patients with VKH disease.

Results

Forty-nine patients with VKH disease were included in this study (31 women and 18 men). The mean age at onset was 50.4 ± 15.4 years and the mean length of follow-up was 40.7 ± 25.5 months. The most common initial treatment was pulse intravenous corticosteroid therapy (89.8%). Fifteen patients developed secondary glaucoma during follow-up. The median time of glaucoma onset from VKH development was 4.5 months (range 0–44 months). Disc swelling type as a pre-treatment factor (p = 0.089, hazard ratio = 7.268), worse final best corrected visual acuity (p = 0.099, odds ratio = 1.545), and cataract progression (p = 0.076, odds ratio = 7.886) as post-treatment factors showed trends for glaucoma development. The patients who progressed to the chronic recurrent stage had more complications including glaucoma.

Conclusion

Secondary glaucoma occurred in more than 30% of patients with VKH disease. The factors that showed a trend toward glaucoma development may reflect an association with delayed treatment initiation and prolonged ocular inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39(4):265–292. https://doi.org/10.1016/s0039-6257(05)80105-5

    Article  CAS  PubMed  Google Scholar 

  2. Gocho K, Kondo I, Yamaki K (2001) Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 42(9):2004–2009

    CAS  PubMed  Google Scholar 

  3. Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawaguchi T et al (2006) Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 47(6):2547–2554. https://doi.org/10.1167/iovs.05-1547

    Article  PubMed  Google Scholar 

  4. Du L, Kijlstra A, Yang P (2016) Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res 52:84–111. https://doi.org/10.1016/j.preteyeres.2016.02.002

    Article  CAS  PubMed  Google Scholar 

  5. Jabs DA, Denniston AK, Dick ADD, Dunn JP, Kramer M, Mccluskey P et al (2021) Classification criteria for Vogt-Koyanagi-Harada Disease. Am J Ophthalmol 228:205–211. https://doi.org/10.1016/J.AJO.2021.03.036

    Article  Google Scholar 

  6. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A (2007) Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 114(3):606–614. https://doi.org/10.1016/j.ophtha.2006.07.040

    Article  PubMed  Google Scholar 

  7. Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 240(10):878–882. https://doi.org/10.1007/S00417-002-0538-Z

    Article  PubMed  Google Scholar 

  8. Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine H, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91(6):e486-493. https://doi.org/10.1111/AOS.12127

    Article  CAS  PubMed  Google Scholar 

  9. Urzua CA, Herbort C, Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A et al (2020) Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect 10(1):23. https://doi.org/10.1186/S12348-020-00214-2

    Article  PubMed  PubMed Central  Google Scholar 

  10. Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, Gupta A, Takeuchi M, Fardeau C et al (2022) Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review. Eye (London) 36(1):29–43. https://doi.org/10.1038/S41433-021-01573-3

    Article  Google Scholar 

  11. Herbort CP, Abu El Asrar AM, Takeuchi M, Pavésio CE, Couto C, Hedayatfar A et al (2019) Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol 39(6):1419–1425. https://doi.org/10.1007/S10792-018-0949-4

    Article  PubMed  Google Scholar 

  12. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE et al (2001) Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131(5):599–606. https://doi.org/10.1016/s0002-9394(01)00937-0

    Article  CAS  PubMed  Google Scholar 

  13. Yang P, Wang C, Su G, Pan S, Qin Y, Zhang J et al (2020) Prevalence, risk factors and management of ocular hypertension or glaucoma in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 105(12):1678–1682. https://doi.org/10.1136/BJOPHTHALMOL-2020-316323

    Article  PubMed  Google Scholar 

  14. Siddique SS, Suelves AM, Baheti U, Foster CS (2013) Glaucoma and uveitis. Surv Ophthalmol 58(1):1–10. https://doi.org/10.1016/j.survophthal.2012.04.006

    Article  PubMed  Google Scholar 

  15. Veerappan M, Fleischman D, Ulrich J, Stinnett S, Jaffe G, Allingham R (2017) The relationship of Vogt-Koyanagi-Harada syndrome to ocular hypertension and glaucoma. Ocul Immunol Inflamm 25(6):748–752. https://doi.org/10.1080/09273948.2016.1189578

    Article  CAS  PubMed  Google Scholar 

  16. Pandey A, Balekudaru S, Venkatramani D, George A, Lingam V, Biswas J (2016) Incidence and management of glaucoma in Vogt Koyanagi Harada disease. J Glaucoma 25(8):674–680. https://doi.org/10.1097/IJG.0000000000000400

    Article  PubMed  Google Scholar 

  17. Takahashi T, Ohtani S, Miyata K, Miyata N, Shirato S, Mochizuki M (2002) A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol 46(5):556–562

    Article  PubMed  Google Scholar 

  18. Forster D, Rao N, Hill R, Nguyen Q, Baerveldt G (1993) Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome. Ophthalmology 100(5):613–618. https://doi.org/10.1016/S0161-6420(93)31604-0

    Article  CAS  PubMed  Google Scholar 

  19. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652. https://doi.org/10.1016/S0002-9394(01)00925-4

    Article  CAS  PubMed  Google Scholar 

  20. Urzua CA, Herbort CP, Takeuchi M, Schlaen A, Concha-del-Rio LE, Usui Y et al (2022) Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review. J Ophthalmic Inflamm Infect 12(1):17. https://doi.org/10.1186/S12348-022-00293-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Okunuki Y, Tsubota K, Kezuka T, Goto H (2015) Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling. Jpn J Ophthalmol 59(2):103–108. https://doi.org/10.1007/S10384-014-0367-8

    Article  PubMed  Google Scholar 

  22. Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057

    Article  PubMed  Google Scholar 

  23. Moorthy RS, Rajeev B, Smith RE, Rao NA (1994) Incidence and management of cataracts in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 118(2):197–204. https://doi.org/10.1016/S0002-9394(14)72899-5

    Article  CAS  PubMed  Google Scholar 

  24. Chee SP, Jap A, Bacsal K (2007) Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol 27(2–3):137–142. https://doi.org/10.1007/S10792-006-9009-6

    Article  PubMed  Google Scholar 

  25. Lai TYY, Chan RPS, Chan CKM, Lam DSC (2009) Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (London) 23(3):543–548. https://doi.org/10.1038/EYE.2008.89

    Article  CAS  Google Scholar 

  26. Abu El-Asrar AM, Van Damme J, Struyf S, Opdenakker G (2021) New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease. Front Med (Lausanne) 8:705796. https://doi.org/10.3389/fmed.2021.705796

    Article  PubMed  Google Scholar 

  27. Herbort CP, Abu El Asrar AM, Yamamoto JH, Pavésio CE, Gupta V, Khairallah M et al (2017) Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol 37(6):1383–1395. https://doi.org/10.1007/S10792-016-0395-0

    Article  PubMed  Google Scholar 

  28. Kim SJ, Yu HG (2007) The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 15(5):381–3817. https://doi.org/10.1080/09273940701624312

    Article  CAS  PubMed  Google Scholar 

  29. Hiyama T, Harada Y, Kiuchi Y (2022) Clinical characteristics and efficacy of adalimumab and low-dose methotrexate combination therapy in patients with Vogt-Koyanagi-Harada disease. Front Med (Lausanne) 8:730215. https://doi.org/10.3389/FMED.2021.730215

    Article  PubMed  Google Scholar 

  30. Hiyama T, Harada Y, Kiuchi Y (2021) Efficacy and safety of adalimumab therapy for the treatment of non-infectious uveitis: efficacy comparison among uveitis aetiologies. Ocul Immunol Inflamm 30(4):951–958. https://doi.org/10.1080/09273948.2020.1857791

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ryan Chastain-Gross, Ph.D., from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. We also thank Gaku Aoki and Tomoyuki Akita, Ph.D., for supporting the statistical analyses.

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8551, Japan

    Suzu Yoshitomi, Yosuke Harada, Tomona Hiyama, Yuki Yuasa, Kazuyuki Hirooka & Yoshiaki Kiuchi

  2. Department of Ophthalmology, Hiroshima Prefectural Hospital, Hiroshima, Japan

    Yuki Yuasa

Authors
  1. Suzu Yoshitomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yosuke Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomona Hiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuki Yuasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyuki Hirooka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiaki Kiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YH contributed to the study conception and design. SY and YH collected data. SY, TH, and YH wrote the article. SY, YY, and KH performed statistical analyses. YK performed critical revision of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yosuke Harada.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethics approval

Ethics approval was approved by Hiroshima University Institutional Review Board.

Consent to participate

Not applicable (consent to participate was waivered because of retrospective design).

Consent to publication

Not applicable (no identity-revealing data were used in the manuscript).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshitomi, S., Harada, Y., Hiyama, T. et al. Incidence and pre/post-treatment risk factors of glaucoma in Vogt-Koyanagi-Harada disease. Int Ophthalmol 43, 2857–2866 (2023). https://doi.org/10.1007/s10792-023-02688-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-023-02688-0

Keywords

Search

Navigation